Emerging Markets A Growth Pillar As Takeda Seeks Turnaround
This article was originally published in PharmAsia News
Emerging markets were one of Takeda's main growth drivers in a fiscal first half with which the company says it was "very pleased" as it seeks to return to sustainable growth and profitability despite the challenges of patent losses that hit its performance in some major markets.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.